questionText: To ask the Secretary of State for Health and Social Care, with reference to the NHS commercial framework for new medicines, updated on 29 January 2025, what assessment he has made of the potential impact of the requirement to provide value at or below the National Institute for Health and Care Excellence cost-effectiveness threshold on access to treatments for (a) rare and (b) ultra-rare diseases.
answerText: Indication-specific pricing can support access to treatments, including for rare conditions, by enabling companies to propose a specific price for smaller indications that would otherwise be commercially unviable under a uniform price.In January 2025, fol...
heading: Rare Diseases: Drugs